Breaking News Instant updates and real-time market news.

PULM

Pulmatrix

$1.33

-0.14 (-9.52%)

07:07
02/08/19
02/08
07:07
02/08/19
07:07

Pulmatrix announces $2.5M registered direct offering priced at-the-market

Pulmatrix announced that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,706,484 shares of common stock at a price of $1.465 per share in a registered direct offering priced at-the-market, resulting in total gross proceeds of approximately $2.5M. The company also agreed to issue to the investors unregistered warrants to purchase up to 1,706,484 shares of common stock. The warrants have an exercise price of $1.34 per share of common stock, will be exercisable immediately and will expire five and one-half years following the date of issuance. The closing of the sale of the securities is expected to take place on or about February 12, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent in connection with the registered direct offering and the concurrent private placement.

PULM Pulmatrix
$1.33

-0.14 (-9.52%)

02/09/18
HCWC
02/09/18
INITIATION
Target $5
HCWC
Buy
Pulmatrix initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Pulmatrix with a Buy rating and $5 price target. The company's iSPERSE platform provides several advantages over conventional inhalation delivery technologies, Fein tells investors in a research note.
02/09/18
02/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Motorola Solutions (MSI) initiated with a Neutral at JPMorgan. 2. Spero Therapeutics (SPRO) initiated with an Overweight at Cantor Fitzgerald. 3. County Bancorp (ICBK) initiated with a Neutral at DA Davidson. 4. Diplomat Pharmacy (DPLO) initiated with a Buy at Lake Street. 5. Pulmatrix (PULM) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/16/18
HCWC
03/16/18
NO CHANGE
Target $3
HCWC
Buy
Pulmatrix price target lowered to $3 from $5 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered his price target for Pulmatrix to $3 citing the expected increase in dilution associated with the proposed equity offering as well increased caution surrounding logic behind the COPD program. The analyst, however, remains optimistic on the Pulmazole development program and keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.